CLASSICAL HODGKIN LYMPHOMA
Clinical trials for CLASSICAL HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CLASSICAL HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for CLASSICAL HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising drug combo aims to cure more High-Risk hodgkin lymphoma patients
⭐️ CURE ⭐️ OngoingThis study tests whether adding the drug nivolumab to standard chemotherapy (ABVD) can improve the chance of cure for people with high-risk Hodgkin lymphoma. It involves 82 untreated patients, first checking safety (Phase I) and then seeing if the combo helps those with stubborn …
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: ⭐️ CURE ⭐️
Last updated Jun 22, 2026 12:09 UTC
-
New combo aims to cure hodgkin lymphoma without harsh chemo or transplant
⭐️ CURE ⭐️ OngoingThis study tests whether combining the drug pembrolizumab with a precise form of radiation can cure people with early-stage Hodgkin lymphoma that has returned or not responded to initial treatment. About 22 participants will receive this combination, with the goal of avoiding the…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: ⭐️ CURE ⭐️
Last updated Jun 22, 2026 12:05 UTC
-
New hope for Hodgkin's: immune-boosting drug plus chemo shows promise
Disease control OngoingThis study tests a new combination treatment for people with advanced classical Hodgkin's lymphoma who have not had treatment before. The drug camrelizumab (which helps the immune system fight cancer) is given together with a standard chemotherapy regimen called AVD. The goal is …
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 22, 2026 12:08 UTC
-
New drug duo aims to control hard-to-treat hodgkin lymphoma
Disease control OngoingThis study tests a combination of two drugs, nivolumab and axatilimab, in adults with classical Hodgkin lymphoma that has returned or not responded to at least one prior treatment, including anti-PD-1 therapy. The main goal is to see if the combination shrinks or controls the can…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 22, 2026 12:05 UTC
-
New tailored therapy offers hope for older hodgkin lymphoma patients
Disease control OngoingThis study tests a treatment plan that adjusts chemotherapy based on a patient's fitness level for adults aged 60 and older with untreated classical Hodgkin lymphoma. All participants receive the immunotherapy drug pembrolizumab plus another targeted drug, then a PET scan and fit…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
New drug combo shows promise for Tough-to-Treat hodgkin lymphoma
Disease control OngoingThis study tests whether combining ibrutinib and nivolumab can help people with classical Hodgkin lymphoma that has returned or not responded to prior treatment. About 18 adults will receive both drugs to see if the cancer shrinks or disappears. The goal is to improve disease con…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC